Skip to Content

Myasthenia­ gravis: Cyclic­and­ Continuous­ Dosing­ of­ Intravenous­ Efgartigimod

Elena Cortes, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain present in this MEDtalk the results of the ADAPT NXT study. This study analyze the efficacy, safety, and tolerability of 10 mg/kg intravenous efgartigimod administered in a cyclic or continuous dosing regimen.

Elena Cortés Vicente

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top